Literature DB >> 14981099

Prophylactic mastectomy for BRCA1/2 carriers: progress and more questions.

Lynn C Hartmann, Amy Degnim, Daniel J Schaid.   

Abstract

Entities:  

Mesh：

Year:  2004        PMID： 14981099     DOI： 10.1200/JCO.2004.01.925

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  12 in total

1.  Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers.

Authors:  Victor R Grann; Priya R Patel; Judith S Jacobson; Ellen Warner; Daniel F Heitjan; Maxine Ashby-Thompson; Dawn L Hershman; Alfred I Neugut
Journal:  Breast Cancer Res Treat       Date:  2010-07-20       Impact factor: 4.872

Review 2.  Evolution of the colored eco-genetic relationship map (CEGRM) for assessing social functioning in women in hereditary breast-ovarian (HBOC) families.

Authors:  June A Peters; Lindsey Hoskins; Sheila Prindiville; Regina Kenen; Mark H Greene
Journal:  J Genet Couns       Date:  2006-11-17       Impact factor: 2.537

3.  Performing and Declining PGD: Accounts of Jewish Israeli Women Who Carry a BRCA1/2 Mutation or Partners of Male Mutation Carriers.

Authors:  Efrat Dagan; Daphna Birenbaum-Carmeli; Eitan Friedman; Baruch Feldman
Journal:  J Genet Couns       Date:  2017-03-06       Impact factor: 2.537

4.  Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.

Authors:  Susan M Domchek; Tara M Friebel; Christian F Singer; D Gareth Evans; Henry T Lynch; Claudine Isaacs; Judy E Garber; Susan L Neuhausen; Ellen Matloff; Rosalind Eeles; Gabriella Pichert; Laura Van t'veer; Nadine Tung; Jeffrey N Weitzel; Fergus J Couch; Wendy S Rubinstein; Patricia A Ganz; Mary B Daly; Olufunmilayo I Olopade; Gail Tomlinson; Joellen Schildkraut; Joanne L Blum; Timothy R Rebbeck
Journal:  JAMA       Date:  2010-09-01       Impact factor: 56.272

Review 5.  Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine.

Authors:  Jeffrey N Weitzel; Kathleen R Blazer; Deborah J MacDonald; Julie O Culver; Kenneth Offit
Journal:  CA Cancer J Clin       Date:  2011-08-19       Impact factor: 508.702

6.  Risk-reduction surgery decisions in high-risk women seen for genetic counseling.

Authors:  Jessica A Ray; Lois J Loescher; Molly Brewer
Journal:  J Genet Couns       Date:  2005-12       Impact factor: 2.537

Review 7.  Cancer in Jews: introduction and overview.

Authors:  Henry T Lynch; Wendy S Rubinstein; Gershon Y Locker
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

8.  Gene expression in histologically normal epithelium from breast cancer patients and from cancer-free prophylactic mastectomy patients shares a similar profile.

Authors:  K Graham; A de las Morenas; A Tripathi; C King; M Kavanah; J Mendez; M Stone; J Slama; M Miller; G Antoine; H Willers; P Sebastiani; C L Rosenberg
Journal:  Br J Cancer       Date:  2010-03-02       Impact factor: 7.640

9.  Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.

Authors:  Noah D Kauff; Susan M Domchek; Tara M Friebel; Mark E Robson; Johanna Lee; Judy E Garber; Claudine Isaacs; D Gareth Evans; Henry Lynch; Rosalind A Eeles; Susan L Neuhausen; Mary B Daly; Ellen Matloff; Joanne L Blum; Paul Sabbatini; Richard R Barakat; Clifford Hudis; Larry Norton; Kenneth Offit; Timothy R Rebbeck
Journal:  J Clin Oncol       Date:  2008-02-11       Impact factor: 44.544

Review 10.  Risk-reducing mastectomy for the prevention of primary breast cancer.

Authors:  Nora E Carbine; Liz Lostumbo; Judi Wallace; Henry Ko
Journal:  Cochrane Database Syst Rev       Date:  2018-04-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.